{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:37:32Z","timestamp":1795117052765,"version":"4.10.3"},"reference-count":20,"publisher":"Innovative Healthcare Institute","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\u2009Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) during chemotherapy is associated with decreased hospitalization rates, improved quality of life, and longer survival. Limited data exist on the benefit of this symptom assessment tool for monitoring immune-related adverse events (irAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\u2009We incorporated irAE-related items from the National Cancer Institute\u2019s (NCI) PRO-CTCAE in a trial evaluating ipilimumab in combination with androgen deprivation therapy in 16 patients with hormone-sensitive prostate cancer. For comparison, NCI\u2019s CTCAE version 4.0 was used by clinicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\u2009IrAE-related PRO-CTCAE surveys and matched CTCAEs (184 pairs) reporting abdominal pain, diarrhea, fatigue, anorexia, nausea, vomiting, rash, and pruritus were collected at each treatment administration and during follow-up. Fatigue, diarrhea, rash, and pruritus were the symptoms most frequently reported by both patients and clinicians. Agreement was lowest for pruritus (\u03ba = 0.10) and highest for rash (\u03ba = 0.64). IrAEs were more commonly reported and of higher grade with PRO-CTCAE scores compared with CTCAE grades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\u2009PRO-CTCAEs focused on irAEs capture the patient\u2019s immunotherapy experience while complementing the clinician\u2019s toxicity assessment measures. Further study is needed to assess PRO-CTCAE\u2019s utility in identifying and managing irAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-23-9","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T07:08:28Z","timestamp":1701500908000},"page":"162-169","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer"],"prefix":"10.36401","volume":"6","author":[{"given":"Daniel Vargas P.","family":"de Almeida","sequence":"first","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"2 Department of Oncology, Oncoclinicas Group, Brasilia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"3 School of Medicine, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Danila","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"4 Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"4 Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan F.","family":"Slovin","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"4 Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Abida","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"4 Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica D.","family":"Cohn","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"5 School of Medicine, New York University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond E.","family":"Baser","sequence":"additional","affiliation":[{"name":"6 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"4 Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA"},{"name":"7 Biomarker Development Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-0390","authenticated-orcid":true,"given":"Karen A.","family":"Autio","sequence":"additional","affiliation":[{"name":"1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"4 Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"2023120212082013300_i2590-017X-6-4-162-b01","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"key":"2023120212082013300_i2590-017X-6-4-162-b02","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"key":"2023120212082013300_i2590-017X-6-4-162-b03","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"2023120212082013300_i2590-017X-6-4-162-b04","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023120212082013300_i2590-017X-6-4-162-b05","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023120212082013300_i2590-017X-6-4-162-b06","article-title":"Division of Cancer Control & Population Sciences;","author":"Correspondence between PRO-CTCAE and CTCAE terminologies"},{"key":"2023120212082013300_i2590-017X-6-4-162-b07","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023120212082013300_i2590-017X-6-4-162-b08","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2023120212082013300_i2590-017X-6-4-162-b09","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41687-019-0111-8","article-title":"Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy","volume":"3","author":"Tolstrup","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"2023120212082013300_i2590-017X-6-4-162-b10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cllc.2019.11.015","article-title":"Patient-reported outcomes from patients receiving immunotherapy or chemoimmunotherapy for metastatic non-small-cell lung cancer in clinical practice","volume":"21","author":"Steffen McLouth","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2023120212082013300_i2590-017X-6-4-162-b11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2023120212082013300_i2590-017X-6-4-162-b12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/s41416-022-01926-z","article-title":"Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE","volume":"127","author":"Watson","year":"2022","journal-title":"Br J Cancer"},{"key":"2023120212082013300_i2590-017X-6-4-162-b13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-020-05928-4","article-title":"A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer","volume":"185","author":"Filho","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2023120212082013300_i2590-017X-6-4-162-b14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2023120212082013300_i2590-017X-6-4-162-b15","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023120212082013300_i2590-017X-6-4-162-b16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"key":"2023120212082013300_i2590-017X-6-4-162-b17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in phase I clinical trials","volume":"113","author":"Veitch","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2023120212082013300_i2590-017X-6-4-162-b18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaad.2019.10.042","article-title":"Health-related quality of life measures and immune checkpoint inhibitors: a systematic review","volume":"82","author":"Walocko","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023120212082013300_i2590-017X-6-4-162-b19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s41687-020-00255-0","article-title":"The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial","volume":"4","author":"Tolstrup","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2023120212082013300_i2590-017X-6-4-162-b20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/4\/162\/3296234\/i2590-017x-6-4-162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/4\/162\/3296234\/i2590-017x-6-4-162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:19Z","timestamp":1765475299000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/6\/4\/article-p162.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,2]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-23-9","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}